Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME.

(RTTNews) - Palantir Technologies Inc. (PLTR) has announced a strategic product partnership with The Nuclear Company to co-develop NOS, the first AI-powered, real-time software system designed ...

On Friday, June 27, we will see the last annual Russel Reconstitution before the index provider switches to reconstitutions twice a year. We’ve covered before that, typically, Russell Reconstitution ...